[
 {
  "trial": "T117",
  "source": "fulltext",
  "arms": {
   "Experimental group (esketamine)": {
    "randomized": "66",
    "analysed": "65"
   },
   "Placebo group": {
    "randomized": "65",
    "analysed": "65"
   }
  },
  "depression": [
   {
    "measure": "MADRS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (MADRS score, median (IQR))",
    "values": {
     "Experimental group (esketamine)": {
      "median": "25",
      "q1": "24",
      "q3": "27",
      "n": "65"
     },
     "Placebo group": {
      "median": "24",
      "q1": "24",
      "q3": "28",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 1,
    "form": "count",
    "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
    "location": "Table 2 (MADRS Response rate, POD 1)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "35",
      "n": "65"
     },
     "Placebo group": {
      "events": "17",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 1,
    "form": "count",
    "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
    "location": "Table 2 (MADRS Remission rate, POD 1)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "22",
      "n": "65"
     },
     "Placebo group": {
      "events": "7",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 1,
    "form": "difference",
    "location": "Results 3.1, paragraph after Table 2 (aMD from mixed-effects model; Figure 2 has no printed values)",
    "estimate": "-1.97",
    "lower": "-3.505",
    "upper": "-0.433",
    "level": "0.95",
    "scale": "mean_difference",
    "values": {
     "Experimental group (esketamine)": {
      "n": "65"
     },
     "Placebo group": {
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 2,
    "form": "count",
    "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
    "location": "Table 2 (MADRS Response rate, POD 2)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "39",
      "n": "65"
     },
     "Placebo group": {
      "events": "26",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 2,
    "form": "count",
    "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
    "location": "Table 2 (MADRS Remission rate, POD 2)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "26",
      "n": "65"
     },
     "Placebo group": {
      "events": "15",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 2,
    "form": "difference",
    "location": "Results 3.1, paragraph after Table 2 (aMD from mixed-effects model; Figure 2 has no printed values)",
    "estimate": "-1.68",
    "lower": "-3.213",
    "upper": "-0.141",
    "level": "0.95",
    "scale": "mean_difference",
    "values": {
     "Experimental group (esketamine)": {
      "n": "65"
     },
     "Placebo group": {
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 3,
    "form": "count",
    "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
    "location": "Table 2 (MADRS Response rate, POD 3)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "48",
      "n": "65"
     },
     "Placebo group": {
      "events": "35",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 3,
    "form": "count",
    "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
    "location": "Table 2 (MADRS Remission rate, POD 3)",
    "values": {
     "Experimental group (esketamine)": {
      "events": "37",
      "n": "65"
     },
     "Placebo group": {
      "events": "15",
      "n": "65"
     }
    }
   },
   {
    "measure": "MADRS",
    "day": 3,
    "form": "difference",
    "location": "Results 3.1, paragraph after Table 2 (aMD from mixed-effects model; Figure 2 has no printed values)",
    "estimate": "-2.046",
    "lower": "-3.582",
    "upper": "-0.510",
    "level": "0.95",
    "scale": "mean_difference",
    "values": {
     "Experimental group (esketamine)": {
      "n": "65"
     },
     "Placebo group": {
      "n": "65"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (PHQ-9 score, median (IQR))",
    "values": {
     "Experimental group (esketamine)": {
      "median": "16",
      "q1": "14",
      "q3": "17",
      "n": "65"
     },
     "Placebo group": {
      "median": "16",
      "q1": "14",
      "q3": "18",
      "n": "65"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2 (PHQ-9 score on POD 3, median (IQR))",
    "values": {
     "Experimental group (esketamine)": {
      "median": "6",
      "q1": "5",
      "q3": "8",
      "n": "65"
     },
     "Placebo group": {
      "median": "8",
      "q1": "6",
      "q3": "12",
      "n": "65"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3 (POD 1: dizziness); Table 2 (POD 1: CADSS score > 0)",
    "values": {
     "Experimental group (esketamine)": {
      "dizziness": "7",
      "dissociation": "1"
     },
     "Placebo group": {
      "dizziness": "7",
      "dissociation": "2"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2300078540",
   "date": null
  },
  "note": "Randomized 66 esketamine / 65 placebo; one esketamine patient was excluded (data lost after discharge on POD 1), so 65/65 analysed. Postoperative MADRS scores are given only as adjusted mean differences (aMD, mixed-effects model with random intercepts; negative favours esketamine) in Results 3.1; Figure 2 prints no values. Minus signs printed as U+2010 hyphens are written '-'. Response and remission counts are participants who improved, not participants with depression; their definitions say so. Postoperative NRS pain (2 h, 4 h, POD 1-3) is only in Supplementary Table S6, not in the source, so pain is empty (Table 1 has preoperative NRS > 3 counts only). Adverse events: one postoperative entry from the first postoperative assessment (POD 1), the one nearest the intraoperative infusion; dizziness 7 vs 7 is also the POD 1-3 total, since the text says no further dizziness occurred on POD 2 or POD 3. Later assessments (esketamine vs placebo), not summable because a participant can count on several days: CADSS > 0 (dissociation) POD 2 1 vs 1, POD 3 3 vs 1, 2 weeks 0 vs 0, 1 month 0 vs 0; dizziness POD 2 0 vs 0, POD 3 0 vs 0. Not mapped: BPRS > 30 (a broad psychopathology threshold, not a combined count of psychiatric events; the source reports dissociation and mania separately, so psychiatric_any does not apply) POD 1 3 vs 4, POD 2 1 vs 4, POD 3 1 vs 4, 2 weeks 1 vs 1, 1 month 0 vs 3; YMRS >= 5 (subclinical hypomania) POD 1 4 vs 3, POD 2 3 vs 1, POD 3 3 vs 1, 2 weeks 3 vs 0, 1 month 2 vs 0; nausea and vomiting (Table 3). Baseline (Table 1): CADSS not 0 4 vs 4, BPRS > 30 0 vs 3, YMRS >= 5 13 vs 21. HADS-A not extracted. No enrollment dates given.",
  "reason": "The coders differed only on adverse events. Coder B's single postoperative entry is kept, because the codebook's adverse-event form holds one count per arm and window with no day; it takes the first postoperative assessment (POD 1, nearest the intraoperative infusion), and dizziness 7 vs 7 is also the POD 1-3 total since the text says no further dizziness occurred. Coder A's per-day entries (POD 2, POD 3, 2 weeks, 1 month) can't be summed into one postoperative count, so they are listed in the note. Coder B's psychiatric_any (BPRS > 30, 3 vs 4) is dropped: BPRS > 30 is a broad-psychopathology threshold already present at baseline (0 vs 3), not a combined count of psychiatric events, and the source reports dissociation and mania separately, so the codebook's condition for psychiatric_any isn't met."
 },
 {
  "trial": "T123",
  "source": "library",
  "arms": {
   "Esketamine group": {
    "randomized": "60",
    "analysed": "57"
   },
   "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
    "randomized": "60",
    "analysed": "55"
   }
  },
  "depression": [
   {
    "measure": "Hamilton Depression Scale (HAMD)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "3",
      "q3": "5.5",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "5",
      "q1": "3",
      "q3": "6",
      "n": "55"
     }
    }
   },
   {
    "measure": "Hamilton Depression Scale (HAMD)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "4",
      "q1": "2",
      "q3": "6",
      "n": "55"
     }
    }
   },
   {
    "measure": "Hamilton Depression Scale (HAMD)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 4, POD two",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "2",
      "q3": "3",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "55"
     }
    }
   },
   {
    "measure": "Hamilton Depression Scale (HAMD)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 4, POD three",
    "values": {
     "Esketamine group": {
      "median": "1",
      "q1": "0.5",
      "q3": "2",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": "55"
     }
    }
   },
   {
    "measure": "Hamilton Depression Scale (HAMD)",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 4, POD seven",
    "values": {
     "Esketamine group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": "55"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "Number of PCIA attempts within 48 h (sufentanil PCIA)",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 2 ('Number of PCIA Attempt (times)')",
    "values": {
     "Esketamine group": {
      "median": "0",
      "q1": "0",
      "q3": "2",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "median": "1",
      "q1": "0",
      "q3": "3",
      "n": "55"
     }
    }
   },
   {
    "measure": "Rescue analgesics (flurbiprofen axetil) within 48 h",
    "day": 2,
    "form": "count",
    "definition": "received rescue flurbiprofen axetil within 48 h",
    "location": "Table 2; Results, secondary outcomes (seven of 57 vs 17 of 55)",
    "values": {
     "Esketamine group": {
      "events": "7",
      "n": "57"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "events": "17",
      "n": "55"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 6 (monitored from the start of PCIA to POD 7)",
    "values": {
     "Esketamine group": {
      "dizziness": "3",
      "psychiatric_any": "0"
     },
     "Sufentanil group (PCIA sufentanil 2 ug/kg only)": {
      "dizziness": "7",
      "psychiatric_any": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-06",
   "end": "2024-11"
  },
  "registration": {
   "number": "ChiCTR2400085319",
   "date": null
  },
  "note": "Randomized 60 per group from Methods ('60 participants in each group were enrolled'); Results say 120 randomized and 8 excluded, leaving the per-protocol 57/55 (Figure 1 not in text). The text is a PDF extraction in which Table 2's esketamine column is printed apart from its rows; it was matched by row order (11 rows), which the text's rescue figures (seven of 57 vs 17 of 55, P = 0.016) and the P values confirm. The NRS rows in Tables 3 and 4 sit under 'Subjective sleep quality', and Methods define that NRS as sleep (0 = best possible sleep), so they are not entered as pain; the Discussion and the mediation analysis (Figure 7, 'NRS1') treat NRS on POD 1-2 as a pain score. If read as pain (sufentanil vs esketamine, median (IQR)): POD 1 3 (3 to 4) vs 3 (2 to 3.5); POD 2 3 (2 to 4) vs 2 (2 to 3); POD 3 2 (1 to 3) vs 2 (1 to 2); POD 7 1 (0 to 2) vs 1 (0 to 1). Postoperative pain NRS is otherwise not printed (Table 1's preoperative pain NRS is 3 (2 to 3) in both groups). PCIA attempts carry no time in Table 2; the PCIA ran 48 h, so day 2. 'Psychiatric symptoms' (Table 6) is a combined count, so psychiatric_any. Postoperative delirium within 3 days (3D-CAM, Table 5), 8 (14.5) vs 5 (8.8) sufentanil vs esketamine, is not mapped: it is a CAM diagnosis over three postoperative days, not agitation or excitement on emergence. Nausea/vomiting, drowsiness and pruritus have no codebook category. Enrollment is the study period in Methods (June 10 to November 30, 2024), which Results refer to ('during this period').",
  "reason": "The only difference was Coder B's agitation 5 vs 8, taken from Table 5's postoperative delirium (3D-CAM within POD 3). The codebook's agitation covers agitation and delirium-like excitement on emergence; a CAM diagnosis of postoperative delirium over three days is a different construct (it includes hypoactive delirium) and the source reports no agitation, so it is left out and recorded in the note, as Coder A did. All other entries match Tables 1-4 and 6; the note adds Coder B's record of the NRS rows read as pain."
 },
 {
  "trial": "T016",
  "source": "fulltext",
  "arms": {
   "Lo-K": {
    "randomized": null,
    "analysed": "226"
   },
   "Hi-K": {
    "randomized": null,
    "analysed": "223"
   },
   "Placebo (P)": {
    "randomized": null,
    "analysed": "221"
   }
  },
  "depression": [
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 2 (Preoperative PHQ-8 score, Median (IQR))",
    "values": {
     "Lo-K": {
      "median": "2",
      "q1": "0",
      "q3": "6",
      "n": "226"
     },
     "Hi-K": {
      "median": "2",
      "q1": "0",
      "q3": "5",
      "n": "223"
     },
     "Placebo (P)": {
      "median": "2",
      "q1": "0",
      "q3": "5",
      "n": "221"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (Preoperative)",
    "values": {
     "Lo-K": {
      "events": "24",
      "n": "226"
     },
     "Hi-K": {
      "events": "22",
      "n": "223"
     },
     "Placebo (P)": {
      "events": "18",
      "n": "221"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 3,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (POD3)",
    "values": {
     "Lo-K": {
      "events": "32",
      "n": "180"
     },
     "Hi-K": {
      "events": "29",
      "n": "169"
     },
     "Placebo (P)": {
      "events": "23",
      "n": "156"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 30,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (POD30)",
    "values": {
     "Lo-K": {
      "events": "9",
      "n": "130"
     },
     "Hi-K": {
      "events": "14",
      "n": "128"
     },
     "Placebo (P)": {
      "events": "24",
      "n": "137"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT01690988",
   "date": null
  },
  "note": "Secondary analysis of PODCAST. Arm numbers are those analysed (Tables 1-2 'Sample size' 221/226/223 of 670); per-arm randomized numbers are only in Fig. 1, which is not reproduced. The baseline is entered twice: the Table 2 median (IQR) and the Table 3 count of PHQ-8 >= 10. Table 2's 'Mean (sd)' row prints 3.1 (0-5), 3.6 (0-6), 3.3 (0-5) for Placebo, Lo-K, Hi-K (all groups 3.3 (3.9)); the parenthesised values repeat the IQRs, so no usable SD is printed and the Median (IQR) row was taken instead (ranges 0-16, 0-22, 0-14). POD30 is 'approximately 1 month after surgery'. Continuous postoperative PHQ-8 is given only as combined ketamine (Lo-K plus Hi-K) vs placebo Hodges-Lehmann median differences: POD3 0 (95% CI -1.0 to 1.0, P=0.773), POD30 0 (95% CI 0.0-1.0, P=0.271); per-group scores are only in Fig. 2 (no printed values), so not recorded. Methods say 165 missing at POD3 and 375 at POD30; Table 3 has 505 and 395 assessed of 670. No adverse events, enrollment dates, or blinding check in this report.",
  "reason": "Coder B also entered the baseline PHQ-8 median (IQR) from Table 2 (Placebo 2 (0-5), Lo-K 2 (0-6), Hi-K 2 (0-5)), which Coder A kept only in the note. The codebook asks for every listed measure at every time the source reports it, before the procedure too, so the baseline score is kept beside the baseline count; median_iqr is the right form because the 'Mean (sd)' row's parentheses repeat the IQRs. All other entries agree with Tables 1-3."
 },
 {
  "trial": "T024",
  "source": "fulltext",
  "arms": {
   "R (ropivacaine alone)": {
    "randomized": null,
    "analysed": "40"
   },
   "RS (ropivacaine with IV S-ketamine)": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "EPDS at discharge",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, 'EPDS scores at admission' (day before surgery)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.5",
      "sd": "2.5",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.9",
      "sd": "2.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS at discharge",
    "day": null,
    "form": "mean_sd",
    "location": "Table 4, 'EPDS scores at discharge'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "4.1",
      "sd": "3.0",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.3",
      "sd": "2.5",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'Resting VAS at 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "0.9",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.4",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'Mobile VAS at 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "5.9",
      "sd": "1.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "3.8",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'PCA times during 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "2.2",
      "sd": "2.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.7",
      "sd": "1.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'Resting VAS at 48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "1.8",
      "sd": "0.7",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'Mobile VAS at 48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "1.1",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.2",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'PCA times during 24-48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.4",
      "sd": "0.9",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 4, Peri-operative outcomes",
    "values": {
     "R (ropivacaine alone)": {
      "nightmare": "0",
      "visual": "0",
      "dizziness": "1"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "nightmare": "25",
      "visual": "0",
      "dizziness": "21"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-01",
   "end": "2021-04"
  },
  "registration": {
   "number": "ChiCTR2000040375",
   "date": "2020-11-28"
  },
  "note": "Sequential (biased-coin up-and-down) dose-finding study: IV S-ketamine 0.15 mg/kg or saline 1 min before surgery under combined spinal-epidural anaesthesia. 85 women recruited and allocated; 40 per group analysed (randomized per arm not stated; Fig. 1 not printed). The design names the measure 'EPDS at discharge'; the baseline EPDS (at admission, the day before surgery) is given under the same name with day -1. The discharge day is not stated, so that entry's day is null. The design's 'analgesic effect at 24 and 48 h' is reported as three Table 4 rows (Resting VAS, Mobile VAS, PCA times), each entered under the design's name with the row named in location, resting VAS first. 'PCA times during 24-48H' is the count within 24-48 h, not cumulative to 48 h. Adverse events are from Table 4 'Peri-operative outcomes' in women awake under neuraxial anaesthesia (coded intraoperative): 'Dreaming' coded nightmare (the source does not say the dreams were unpleasant), 'Blurred vision' coded visual. Not mapped: the sedation scale's 'agitated' (score 1) counts, RS vs R, before delivery 0 vs 12, 5 min after delivery 0 vs 3, end of surgery 0 vs 0, which are sedation levels rather than adverse events. Enrollment period is from Methods ('recruited during January 2021 and April 2021'; Results don't state it); registration date printed 28/11/2020. Results text gives 'Duration of first PCA' in the reverse group order to Table 4 (not extracted).",
  "reason": "Both coders entered the same Table 4 values for mobile VAS and PCA times, but Coder B named them with the source's names ('Mobile VAS', 'PCA times') while Coder A used the design's 'analgesic effect at 24 and 48 h'. Measure names follow the design, and the source reports the design's analgesic effect as exactly these three rows, so Coder A's entries are kept, each row named in location with resting VAS first. All values were checked against Table 4; the note adds that the 24-48H PCA count covers only that interval."
 },
 {
  "trial": "T026",
  "source": "fulltext",
  "arms": {
   "Group C": {
    "randomized": "30",
    "analysed": "30"
   },
   "Group K": {
    "randomized": "30",
    "analysed": "30"
   }
  },
  "depression": [
   {
    "measure": "Profile of Mood States (POMS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4, 'Total depression subscale', Pre",
    "values": {
     "Group C": {
      "mean": "8.4",
      "sd": "2.8",
      "n": "30"
     },
     "Group K": {
      "mean": "8.1",
      "sd": "2.3",
      "n": "30"
     }
    }
   },
   {
    "measure": "Profile of Mood States (POMS)",
    "day": 0,
    "form": "mean_sd",
    "location": "Table 4, 'Total depression subscale', Post (2 h postoperatively)",
    "values": {
     "Group C": {
      "mean": "10.2",
      "sd": "3.4",
      "n": "30"
     },
     "Group K": {
      "mean": "5.3",
      "sd": "1.9",
      "n": "30"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 5, Diplopia, Intraoperative",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "9"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 5, Diplopia, Postoperative",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "6"
     }
    }
   },
   {
    "window": "overall",
    "location": "Table 5, Perioperative psychedelic phenomena",
    "values": {
     "Group C": {
      "hallucination": "0",
      "dissociation": "0"
     },
     "Group K": {
      "hallucination": "2",
      "dissociation": "6"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2019-07",
   "end": "2020-08"
  },
  "registration": {
   "number": "PACTR201907779292947",
   "date": "2019-07-16"
  },
  "note": "Randomized per arm taken from the tables' N = 30 (60 participated, 1:1, no losses reported; Fig. 1 not printed). Design code POMS_D, so the entries are Table 4's 'Total depression subscale' (Pre = preoperatively, day -1; Post = 2 h postoperatively, day 0). Total POMS (total mood disturbance, the paper's primary outcome; Table 4) is not a measure the design lists, so not entered: Preoperative K 28.1 ± 8.0, C 27.8 ± 9.5; Postoperative K 11.9 ± 5.4, C 37.3 ± 13.0. Table 5: diplopia coded visual; 'Perioperative psychedelic phenomena' (assessed intraoperatively, during infusion, and/or postoperatively) coded overall; not coded: relaxation 25 vs 0, euphoria 7 vs 0, dysphoria 1 vs 0, headache intraoperative 6 vs 0 and postoperative 7 vs 6 (K vs C). Registration date printed 16/7/2019.",
  "reason": "Coder B added 'Total POMS' entries (total mood disturbance) under the source's name. The design lists only the POMS depression measure (code POMS_D), which both coders entered as Table 4's total depression subscale; total mood disturbance isn't a depression measure the design lists, and measure names follow the design, so it stays in the note, as Coder A did. All other values were checked against Tables 4 and 5."
 }
]